DE1450454U
(https= )
US6919370B2
(en )
2005-07-19
Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
Sessink et al.
1999
Evaluation of the PhaSeal hazardous drug containment system
Begley et al.
2020
Lenacapavir sustained delivery formulation supports 6-month dosing interval
US20190145741A1
(en )
2019-05-16
Tactical wall panel, assembly and methods of deployment and use
DE2162701A1
(de )
1973-06-28
Bekleidungsstueck zum schutz gegen energiereiche projektile
EP4065922B1
(de )
2023-10-04
Modulare schutzbekleidungseinheit sowie deren verwendung
Kanj et al.
2023
The battle against fungi: lessons in antifungal stewardship from COVID 19 times
Ibrahim et al.
1983
The use of chloranil for spectrophotometric determination of some tranquillizers and antidepressants
Schneider et al.
2016
Management of HCV-associated liver cirrhosis
GB973822A
(en )
1964-10-28
Improvements relating to cubic boron nitride
Gaddoni et al.
1993
Contact dermatitis among decorators and enamellers in hand-made ceramic decorations.
DE1517474U
(https= )
Hoesley et al.
1997
Overview of oral azole drugs as systemic antifungal therapy
Murskyj
2020
Disseminated histoplasmosis after vedolizumab treatment for ulcerative colitis
ES2304163T3
(es )
2008-09-16
Solucion inyectable esteril estable, lista para usar, de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona; sistema cerrado para envasar solucion; procedim. eliminar residuos alcalinos cristales de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona.
DE1487257U
(https= )
CN211584289U
(zh )
2020-09-29
一种新型便于艾滋病人使用的药盒
Prugnard et al.
1996
Chemistry and structure-activity relationships of biguanides
CN215641145U
(zh )
2022-01-25
化学品物理危险性鉴定用远距检测装置
KR910016707A
(ko )
1991-11-05
5-페닐-1h-피라졸-4-프로피온산 유도체, 그 제조 및 사용방법.
Kononenko et al.
2018
Experimental rationale of selection of the hypoglicemic dose of ginger dry extract on normoglycemic rats
林慧
2025
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer
PL246350B1
(pl )
2025-01-13
Pochodne kwasu (2,4-diokso-1,3-tiazolidyn-3-ylo)octowego, sposób ich wytwarzania oraz ich zastosowanie medyczne
DE1393185U
(https= )